End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
40 THB | -1.23% | -1.23% | -0.62% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.62% | 957M | B | ||
+26.08% | 681B | C+ | ||
+21.85% | 556B | B | ||
-4.77% | 361B | C+ | ||
+16.97% | 325B | B- | ||
+5.69% | 285B | C+ | ||
+13.68% | 235B | B+ | ||
+3.65% | 199B | B- | ||
-11.12% | 189B | A+ | ||
-3.40% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEGA Stock
- Ratings Mega Lifesciences